Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 908 matching trials from the live ClinicalTrials.gov search.
Conditions
Age-Related Macular Degeneration
Interventions
DE-120, Aflibercept
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
Conditions
Retinitis Pigmentosa
Interventions
Minocycline
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

CEI Van Outreach Screening Study

NCT01510392
Conditions
Glaucoma, Macular Disease, Keratoconus
Interventions
OCT imaging, the FDA Cleared iVue
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Recalcitrant Wet Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Mountain View, California
Conditions
Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related, Maculopathy, Age-Related, Retinal Degeneration, Retinal Neovascularization, Gene Therapy, Therapy, Gene, Eye Diseases
Interventions
AAV2-sFLT01
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Worcester, Massachusetts + 1 more
Conditions
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Interventions
Vitamin A Palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Interventions
EYE201
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Modesto, California • Mountain View, California + 21 more
Conditions
Age-related Macular Degeneration
Interventions
Conjunctival and nasopharyngeal bacteria cultures
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Geographic Atrophy
Interventions
Vonaprument
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
50 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Sarasota, Florida • St. Petersburg, Florida • Hagerstown, Maryland + 3 more
Conditions
Geographic Atrophy
Interventions
BRX011, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
55 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Gilbert, Arizona • Phoenix, Arizona • Hattiesburg, Mississippi + 8 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Thickness Module

NCT04428242
Conditions
Macular Edema, Macular Degeneration
Interventions
RHMS-RTM, SD-OCT
Device · Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sacramento, California
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Ranibizumab, Peripheral Laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Geographic Atrophy
Interventions
Placebo-matching BI 1584862, BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Conditions
Age Related Macular Degeneration
Interventions
Self management program 'Living with Vision Loss'
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
55 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Stargardt Disease
Interventions
ALK-001, Placebo
Drug
Lead sponsor
Alkeus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 45 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
14
States / cities
Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more
Conditions
Age-related Macular Degeneration, Geographic Atrophy
Interventions
VOY-101
Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Conditions
Age-related Macular Degeneration
Interventions
RBM-007 Injectable Solution
Drug
Lead sponsor
Ribomic USA Inc
Industry
Eligibility
55 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Sacramento, California • Stanford, California • Walnut Creek, California
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
369,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Age-Related Macular Degeneration
Interventions
ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
Drug
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Village-Integrated Eye Worker Trial II

NCT03752840
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
60,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Retinal Degeneration, Age-Related Macular Degeneration, Retinitis Pigmentosa, Hydroxychloroquine Retinopathy, Usher Syndromes, Late-Onset Retinal Degeneration, Cone Dystrophy, Cone Rod Dystrophy, Rod Cone Dystrophy, Rod Dystrophy
Interventions
Adaptive optics imaging
Device
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2021 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
MK-8748, Aflibercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Glendale, California • Sacramento, California • Denver, Colorado + 18 more
Conditions
Age Related Maculopathy, Retinal Degeneration
Interventions
Eccentric Viewing Training for Reading
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois